Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459682 | 1.00 | ACACB (0.33) | ACACBALOX15SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29259340 | 0.85 | ALOX15 (0.36) | ACACBALOX15SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9956904 | 0.85 | ALOX15 (0.33) | ACACBALOX15SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9956901 | 0.85 | ALOX15 (0.33) | ACACBALOX15SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2925772 | 0.80 | LMNA (0.38) | SMN1; SMN2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL2925771 | 0.80 | LMNA (0.38) | SMN1; SMN2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL30781497 | 0.79 | ALDH1A1 (0.37) | ALOX15SMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL1555344 | 0.78 | ALDH1A1 (0.38) | SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL1554250 | 0.78 | ALDH1A1 (0.38) | SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL1554251 | 0.78 | ALDH1A1 (0.38) | SMN1; SMN2KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367687-B2 | Pyrazole derivatives | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2231636-B1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS INHIBITORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20100280033-A1 | Pyrazole Derivatives | NOVARTIS AG | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280033-A1 | Pyrazole Derivatives | PRKDC, PRKACA, PDK2 | ACACB 908/4885ALOX15 3231/4885SMN1; SMN2 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.